Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BIOCON Limited has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners and 4 distinct art units. This one-to-one ratio between actions, examiners, and art units indicates that each pending application is being evaluated independently by different personnel in different administrative groups. The busiest examiner for the portfolio is HIBBERT, CATHERINE S, who is managing 1 pending office action.
Because each of the 4 pending actions is with a different examiner, the company must manage four separate prosecution tracks within the Biotechnology & Pharmaceuticals field. This diversity across 4 art units suggests a range of technical subjects within the company's pharmaceutical portfolio. Practitioners should be prepared for 4 distinct examination styles, as the lack of overlap between the 4 examiners and 4 art units prevents the development of a unified prosecution approach based on a single examiner's tendencies. The 4 pending office actions represent the current active workload, and their resolution will impact the company's overall standing in the Biotechnology & Pharmaceuticals sector. Navigating these 4 distinct environments requires a versatile strategy that addresses the unique requirements of each examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
| GEORGE, DENNIS CHERIAN | 1 | 42.9% | +72.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682254 | PURIFICATION OF LIRAGLUTIDE | HIBBERT, CATHERINE S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682254 | PURIFICATION OF LIRAGLUTIDE | HIBBERT, CATHERINE S | — |
| 18335542 | USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6 | GEORGE, DENNIS CHERIAN | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682254 | PURIFICATION OF LIRAGLUTIDE | HIBBERT, CATHERINE S | 1658 | §103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18335542 | USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6 | GEORGE, DENNIS CHERIAN | 1644 | §103§112DP | Final Rejection | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOCON Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Catherine S Hibbert has the most, with 1 of BIOCON Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
